Clinical Scorecard: Impact of Enhanced Intermittent Theta Burst Stimulation on Depressive Symptoms and Cognitive Abilities in Adolescents with Bipolar Disorder

At a Glance

Key Highlights

• Bipolar depression in adolescents lacks FDA-approved pharmacotherapies and has high disease burden with predominant depressive episodes
• aiTBS offers a shorter, potentially better-tolerated neuromodulation alternative to conventional high-frequency rTMS and electroconvulsive therapy
• Preliminary evidence suggests aiTBS may improve depressive symptoms and cognitive functions in adolescents with bipolar depression, but research remains limited

Guideline-Based Recommendations

Diagnosis

• Confirm Bipolar Disorder II diagnosis using DSM-5 criteria by experienced psychiatrists
• Assess depressive severity with standardized scales such as HAMD-24 (score ≥ 20 for inclusion)

Management

• Consider aiTBS targeting left dorsolateral prefrontal cortex as adjunctive treatment for depressive episodes in adolescents with BD
• Avoid recent ECT or TMS treatments within 6 months prior to aiTBS to reduce confounding effects
• Exclude patients with neurological contraindications or implanted ferromagnetic materials incompatible with TMS

Monitoring & Follow-up

• Monitor depressive symptom changes using validated rating scales (e.g., MADRS, HAMD-24)
• Assess cognitive functions pre- and post-treatment to evaluate potential cognitive benefits or adverse effects
• Observe for treatment-emergent affective switching or adverse events during aiTBS sessions

Risks

• Potential risk of manic switch with antidepressants in bipolar depression necessitates cautious use
• Conventional HF-rTMS may cause scalp discomfort limiting tolerability; aiTBS may improve tolerability
• Limited data on safety and neurodevelopmental impact of aiTBS in adolescents warrant careful patient selection and monitoring

Patient & Prescribing Data

Adolescents aged 10-19 years with Bipolar Disorder II experiencing depressive episodes

aiTBS administered as multiple daily sessions delivering 1800 pulses targeting left DLPFC may reduce depressive symptoms and improve cognitive abilities; treatment duration shorter than conventional rTMS protocols

Clinical Best Practices

• Obtain informed consent from patients and guardians prior to enrollment
• Screen thoroughly for neurological and psychiatric comorbidities and contraindications to TMS
• Use standardized diagnostic and severity assessment tools to ensure appropriate patient selection
• Implement aiTBS protocols with attention to stimulation parameters to maximize efficacy and tolerability
• Monitor cognitive function alongside mood symptoms to assess comprehensive treatment effects
• Avoid concurrent structured psychotherapies during study period to isolate aiTBS effects

References

• McGirr et al. Meta-analysis on rTMS in Bipolar Disorder
• Beynel et al. iTBS efficacy in Bipolar Depression
• Hamilton Depression Rating Scale (HAMD-24)